238 related articles for article (PubMed ID: 34424409)
21. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
22. Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement.
Assié JB; Jean D
Expert Opin Ther Targets; 2023; 27(11):1059-1069. PubMed ID: 37902459
[TBL] [Abstract][Full Text] [Related]
23. Optimal Therapy of Advanced Stage Mesothelioma.
Disselhorst MMJ; Burgers SJA; Baas P
Curr Treat Options Oncol; 2017 Aug; 18(8):48. PubMed ID: 28681207
[TBL] [Abstract][Full Text] [Related]
24. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy approaches for malignant pleural mesothelioma.
Fennell DA; Dulloo S; Harber J
Nat Rev Clin Oncol; 2022 Sep; 19(9):573-584. PubMed ID: 35778611
[TBL] [Abstract][Full Text] [Related]
26. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
[TBL] [Abstract][Full Text] [Related]
27. [Advances in Targeted Therapy for Malignant Pleural Mesothelioma].
Fu F; Zhang Y; Shen H
Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):391-398. PubMed ID: 38880927
[TBL] [Abstract][Full Text] [Related]
28. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
Facchetti G; Petrella F; Spaggiari L; Rimoldi I
Eur J Med Chem; 2017 Dec; 142():266-270. PubMed ID: 28800871
[TBL] [Abstract][Full Text] [Related]
29. Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.
Chia PL; Russell PA; Scott AM; John T
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1235-1245. PubMed ID: 27696931
[TBL] [Abstract][Full Text] [Related]
30. New Concepts in the Treatment of Malignant Pleural Mesothelioma.
Wald O; Sugarbaker DJ
Annu Rev Med; 2018 Jan; 69():365-377. PubMed ID: 29029582
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
Parikh K; Hendriks LEL; Bironzo P; Remon J
Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
[TBL] [Abstract][Full Text] [Related]
32. Current treatments and trials in malignant pleural mesothelioma.
Bibby AC; Maskell NA
Clin Respir J; 2018 Jul; 12(7):2161-2169. PubMed ID: 30129116
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the treatment of malignant pleural mesothelioma.
Ramalingam SS; Belani CP
J Thorac Oncol; 2008 Sep; 3(9):1056-64. PubMed ID: 18758312
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
35. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.
Calabrò L; Bronte G; Grosso F; Cerbone L; Delmonte A; Nicolini F; Mazza M; Di Giacomo AM; Covre A; Lofiego MF; Crinò L; Maio M
Front Immunol; 2023; 14():1333661. PubMed ID: 38259475
[TBL] [Abstract][Full Text] [Related]
39. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation.
Chen YL; Chang MC; Chiang YC; Lin HW; Sun NY; Chen CA; Sun WZ; Cheng WF
Cancer Lett; 2018 Jul; 425():152-163. PubMed ID: 29596890
[TBL] [Abstract][Full Text] [Related]
40. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
Christoph DC; Eberhardt WE
Curr Opin Oncol; 2014 Mar; 26(2):171-81. PubMed ID: 24441503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
